Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.75 +14.6%	$2.51	$0.40 ▼ $5.48	$40.76M	0.27	565,693 shs	319,964 shs
CRGX CARGO Therapeutics	$4.49 +0.4%	$4.42	$3.00 ▼ $25.45	$206.11M	0.28	3.18 million shs	673,476 shs
FDMT 4D Molecular Therapeutics	$6.42 +42.7%	$4.21	$2.23 ▼ $17.41	$208.46M	2.83	360,319 shs	31.47 million shs
RAPT Rapt Therapeutics	$10.49 -2.9%	$9.23	$5.67 ▼ $26.56	$178.59M	0.01	98,493 shs	31,794 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+14.58%	-8.64%	-11.29%	+161.90%	+252.93%
CRGX CARGO Therapeutics	+0.45%	-0.66%	+2.05%	+3.94%	-73.63%
FDMT 4D Molecular Therapeutics	+42.67%	+40.48%	+48.96%	+70.74%	-63.79%
RAPT Rapt Therapeutics	-2.87%	-21.19%	+30.96%	+35.63%	-58.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.5105 of 5 stars	0.0	5.0	0.0	0.6	0.8	0.0
CRGX CARGO Therapeutics	2.0111 of 5 stars	2.9	0.0	0.0	1.9	1.7	1.3
FDMT 4D Molecular Therapeutics	2.513 of 5 stars	3.3	3.0	0.0	2.5	1.7	0.6
RAPT Rapt Therapeutics	4.0052 of 5 stars	3.3	1.0	4.2	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	242.98% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	360.37% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$20.57	96.11% Upside

Current Analyst Ratings Breakdown

Latest ABVC, RAPT, CRGX, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	91.56	N/A	N/A	$0.06 per share	45.83
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	7,435.97	N/A	N/A	$11.05 per share	0.58
RAPT Rapt Therapeutics	$1.53M	113.40	N/A	N/A	$11.51 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-45.93%	-39.58%	8/11/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest ABVC, RAPT, CRGX, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CRGX CARGO Therapeutics	-$0.42	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
CRGX CARGO Therapeutics	N/A	6.30	6.30
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
CRGX CARGO Therapeutics	93.16%
FDMT 4D Molecular Therapeutics	99.27%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
CRGX CARGO Therapeutics	2.92%
FDMT 4D Molecular Therapeutics	9.60%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
CRGX CARGO Therapeutics	116	46.11 million	44.76 million	N/A
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

ABVC, RAPT, CRGX, and FDMT Headlines

Recent News About These Companies

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1 at 10:56 AM | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded to Neutral at JPMorgan Chase & Co.

August 1 at 2:16 AM | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31 at 7:33 AM | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30 at 11:42 PM | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30 at 11:42 PM | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30 at 11:42 PM | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

July 28, 2025 | americanbankingnews.com

What is Lifesci Capital's Estimate for RAPT Q2 Earnings?

July 27, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

Lifesci Capital Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Strong-Buy

July 25, 2025 | americanbankingnews.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

July 23, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board

July 15, 2025 | tmcnet.com

Best Momentum Stocks to Buy for July 15th

July 15, 2025 | zacks.com

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, RAPT, CRGX, and FDMT Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.75 +0.35 (+14.58%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.78 +0.04 (+1.27%)

As of 08/1/2025 07:32 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

CARGO Therapeutics NASDAQ:CRGX

$4.49 +0.02 (+0.45%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.44 -0.04 (-1.00%)

As of 08/1/2025 07:11 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

4D Molecular Therapeutics NASDAQ:FDMT

$6.42 +1.92 (+42.67%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.38 -0.04 (-0.64%)

As of 08/1/2025 08:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Rapt Therapeutics NASDAQ:RAPT

$10.49 -0.31 (-2.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.03 (+0.24%)

As of 08/1/2025 07:04 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time